ClinicalTrials.gg

TargetBeta

MAP2K1

mitogen-activated protein kinase kinase 1 · also MEK1, MAPKK1, MKK1, PRKMK1 · Mitogen-activated protein kinase kinases

5 programs in company-led studies act on MAP2K1, from 4 companies: 2 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
cobimetinibruleHoffmann-La Rochephase 3386 runningMAP2K2ChEMBL
luvometinibruleFosun Pharmaphase 366 running–the studies' text
mirdametinibruleMerck KGaA, Darmstadt, Germanyphase 294 runningMAP2K2ChEMBL
pimasertibruleMerck KGaA, Darmstadt, Germanyphase 2130 runningMAP2K2NCIt
polfurmetinibPfizerphase 131 runningMAP2K2the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.